Home » Stocks » Kezar Life Sciences

Kezar Life Sciences, Inc. (KZR)

Stock Price: $5.74 USD 0.11 (1.95%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 265.51M
Revenue (ttm) n/a
Net Income (ttm) -38.24M
Shares Out 46.26M
EPS (ttm) -1.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $5.74
Previous Close $5.63
Change ($) 0.11
Change (%) 1.95%
Day's Open 5.62
Day's Range 5.59 - 5.80
Day's Volume 107,944
52-Week Range 2.18 - 9.79

More Stats

Market Cap 265.51M
Enterprise Value 113.97M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 46.26M
Float 37.72M
EPS (basic) -1.50
EPS (diluted) -1.34
FCF / Share -0.79
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.50M
Short Ratio 7.00
Short % of Float 3.97%
Beta 0.13
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.69
Revenue n/a
Operating Income -40.01M
Net Income -38.24M
Free Cash Flow -34.05M
Net Cash 151.54M
Net Cash / Share 3.28
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -18.28%
ROE -30.24%
ROIC -36.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(126.48% upside)
Current: $5.74
Target: 13.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-37.34-24.73-8.75-8.99
Net Income-35.09-23.17-8.52-8.99
Shares Outstanding19.0810.260.600.34
Earnings Per Share-1.84-2.26-14.21-26.56
Operating Cash Flow-29.88-20.79-8.11-9.76
Capital Expenditures-0.61-1.11-0.39-0.13
Free Cash Flow-30.48-21.90-8.50-9.89
Cash & Equivalents78.2110751.05-
Total Debt6.36---
Net Cash / Debt71.8410751.05-
Book Value78.05109-25.69-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kezar Life Sciences, Inc.
Country United States
Employees 40
CEO John Fowler

Stock Information

Ticker Symbol KZR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KZR
IPO Date June 21, 2018


Kezar Life Sciences, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is headquartered in South San Francisco, California.